Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/18502
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKarassa, F. B.en
dc.contributor.authorBijl, M.en
dc.contributor.authorDavies, K. A.en
dc.contributor.authorKallenberg, C. G.en
dc.contributor.authorKhamashta, M. A.en
dc.contributor.authorManger, K.en
dc.contributor.authorMichel, M.en
dc.contributor.authorPiette, J. C.en
dc.contributor.authorSalmon, J. E.en
dc.contributor.authorSong, Y. W.en
dc.contributor.authorTsuchiya, N.en
dc.contributor.authorYoo, D. H.en
dc.contributor.authorIoannidis, J. P.en
dc.date.accessioned2015-11-24T18:53:07Z-
dc.date.available2015-11-24T18:53:07Z-
dc.identifier.issn0004-3591-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/18502-
dc.rightsDefault Licence-
dc.subjectAntigens, CD/*geneticsen
dc.subjectAntiphospholipid Syndrome/*epidemiology/*geneticsen
dc.subjectBias (Epidemiology)en
dc.subjectGenetic Predisposition to Disease/epidemiologyen
dc.subjectHumansen
dc.subjectLupus Erythematosus, Systemic/epidemiology/geneticsen
dc.subjectPolymorphism, Geneticen
dc.subjectReceptors, IgG/*geneticsen
dc.subjectRisk Factorsen
dc.subjectSensitivity and Specificityen
dc.titleRole of the Fcgamma receptor IIA polymorphism in the antiphospholipid syndrome: an international meta-analysisen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.primary10.1002/art.11059-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/12847687-
heal.identifier.secondaryhttp://onlinelibrary.wiley.com/store/10.1002/art.11059/asset/11059_ftp.pdf?v=1&t=h0jeohg6&s=e6eaa509659861be49e521f9602225d9c6672281-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2003-
heal.abstractOBJECTIVE: To assess the impact of the FcgammaRIIA-R/H131 polymorphism on the risk for antiphospholipid syndrome (APS), both primary and secondary to systemic lupus erythematosus (SLE). METHODS: This international meta-analysis combined data from 9 research teams. FcgammaRIIA-R/H131 genotypes were determined in 481 APS cases (206 with primary APS), 1,420 SLE controls, and 1,655 disease-free controls. Data were combined using fixed-effects and random-effects models. RESULTS: Compared with disease-free controls, the RR genotype was enriched in the entire group of APS cases (odds ratio [OR] 1.65, 95% confidence interval [95% CI] 1.28-2.14); this was driven mostly by patients with secondary APS (OR 1.95, 95% CI 1.45-2.63). The excess of RR homozygotes but not heterozygotes among APS patients suggested a recessive mode of inheritance, rather than the additive model seen for SLE susceptibility, where RR conferred greatest risk, and RH intermediate risk, for SLE. This probably reflected the additional influence of another opposing genetic effect of HH homozygosity on APS predisposition (OR 0.72 for RH versus HH, 95% CI 0.55-0.96). Among SLE patients, those with APS were more frequently HH homozygotes than heterozygotes (OR 0.56 for RH versus HH, 95% CI 0.39-0.81). HH homozygosity also tended to predominate in primary APS compared with secondary APS (OR 0.50 for RR versus HH, 95% CI 0.25-0.99 by fixed-effects model). There was no significant between-study heterogeneity for any of these effects. CONCLUSION: The FcgammaRIIA-R/H131 polymorphism is an important determinant of predisposition to APS, with different influences on SLE and APS susceptibility per se.en
heal.journalNameArthritis Rheumen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Files in This Item:
File Description SizeFormat 
Karassa-2003-Role of the Fcgamma.pdf104.42 kBAdobe PDFView/Open    Request a copy


This item is licensed under a Creative Commons License Creative Commons